In addition, the ESC guide recommends that type 1 diabetes mellitus is not an absolute contraindication, but an individual risk of ketoacidosis should be considered when starting SGLT2 inhibitors therapy (160). This evidence concerns the gene SLC5A2 and diabetes mellitus.